Clinical outcome prediction of percutaneous cementoplasty for metastatic bone tumor using 18F-FDG PET-CT
- 208 Downloads
Percutaneous cementoplasty (PC) is used for metastatic bone tumor. Bone metastases patients who are unable to avail regular surgery, because of their poor general condition, undergo PC to gain mechanical stability and pain relief. We evaluated the effect of PC using 18F-FDG PET-CT and investigated the correlation and predictability between quantitative parameters of 18F-FDG PET-CT and pain status after PC.
Subjects comprised 18 patients (total 32 sites) who had undergone PC for the metastatic bone tumors. Pain degree of the patients was obtained by visual analog scale (VAS) in the pre-PC, immediate post-PC, and follow-up post-PC state. As PET-CT parameters, maximum and mean standardized uptake value (MaxSUV and MeanSUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Receiver operator characteristic curve analysis was performed for pre-PC, post-PC PET-CT, and delta (Δ) values of PET-CT parameters to correlate and predict the good pain improvement (VAS pain ≤2) after the PC procedure.
Patients’ pain status improved significantly in immediate post-PC and follow-up post-PC pain (all p < 0.001). Among PET-CT parameters, MaxSUV (p = 0.004) and MeanSUV (p = 0.007) showed significant interval decrease after PC procedure. All of the post-PC PET-CT and ΔPET-CT values showed significant prediction of pain improvement for follow-up post-PC pain, especially ΔTLG (AUC = 0.804, p = 0.0003) and ΔMTV (AUC = 0.804, p = 0.0004).
There was significant reduction of patients’ pain after PC, and ΔTLG and ΔMTV of PET-CT parameters showed best predictability for follow-up post-PC pain improvement. PET-CT can be the useful parameter to predict treatment response of PC.
KeywordsPositron emission tomography Percutaneous cementoplasty Bone metastasis Visual analog scale Standardized uptake value Total lesion glycolysis
Conflict of interest
The authors have no potential conflict of interest.
- 25.Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte J-J, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5:612–9.PubMedGoogle Scholar
- 28.Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.PubMedCrossRefGoogle Scholar